BASECAMP Phase 2 topline data expected in Q1 2027 MRI-measured muscle fat fraction selected as the primary efficacy endpoint for BASECAMPForazapadin cleared to begin clinical evaluation for FSHD in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results